New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/161275 |
Resumo: | Rare Diseases (RDs) pose a significant challenge. Almost 8,000 RDs are known, but only 200 have a treatment. The development of drugs is an extensive and costly process and in silico tools have gained a particular interest in the last decade by giving insights into drug metabolization and interaction with biological targets. Defective glycosylation leads to a family of RDs known as congenital disorders of glycosylation (CDG). GNE Myopathy (GNEM) is an ultra-rare CDG caused by mutations in the GNE gene responsible for encoding the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase that regulates the sialic acid biosynthesis. To date, there is no approved therapy for GNEM but supplementation approaches with sialic acid and its precursors have been studied. In this work, in silico tools were used to explore the absorption, distribution, metabolism, excretion and toxicity properties, as well as off-target interactions of five novel prodrugs (PGNE 1-5) for treating GNEM. These prodrugs are predicted to have a potential advantage in terms of absorption when compared with N-acetylmannosamine, which is currently in a phase 2 clinical trial. However, PGNE 1-5 display concerning toxicological indicators namely related to hepatotoxicity. These alerts may be attributed to interactions with proteins involved in distribution (P-glycoprotein) and metabolism (cytochrome P450 3A4 and carboxylesterase 1). To evaluate the extension of the hepatotoxicity predictions and the safety of the prodrugs, in vitro studies were conducted by using a hepatic and a GNEM cell model, respectively. The viability assays did not confirm the toxicity alerts and indicate that the prodrugs are safe within the tested concentrations. In conclusion, while in silico assessments raised concerns about potential hepatotoxicity, our in vitro studies promised the safety of the tested prodrugs, emphasizing the urgency of investigating their efficacy as prospective treatments for GNEM. |
id |
RCAP_bd646ea00157cfa1596022515a042b2f |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/161275 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipelineGlycosylationGNE MyopathySialic acidProdrugsHepatotoxicityDomínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e TecnologiasRare Diseases (RDs) pose a significant challenge. Almost 8,000 RDs are known, but only 200 have a treatment. The development of drugs is an extensive and costly process and in silico tools have gained a particular interest in the last decade by giving insights into drug metabolization and interaction with biological targets. Defective glycosylation leads to a family of RDs known as congenital disorders of glycosylation (CDG). GNE Myopathy (GNEM) is an ultra-rare CDG caused by mutations in the GNE gene responsible for encoding the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase that regulates the sialic acid biosynthesis. To date, there is no approved therapy for GNEM but supplementation approaches with sialic acid and its precursors have been studied. In this work, in silico tools were used to explore the absorption, distribution, metabolism, excretion and toxicity properties, as well as off-target interactions of five novel prodrugs (PGNE 1-5) for treating GNEM. These prodrugs are predicted to have a potential advantage in terms of absorption when compared with N-acetylmannosamine, which is currently in a phase 2 clinical trial. However, PGNE 1-5 display concerning toxicological indicators namely related to hepatotoxicity. These alerts may be attributed to interactions with proteins involved in distribution (P-glycoprotein) and metabolism (cytochrome P450 3A4 and carboxylesterase 1). To evaluate the extension of the hepatotoxicity predictions and the safety of the prodrugs, in vitro studies were conducted by using a hepatic and a GNEM cell model, respectively. The viability assays did not confirm the toxicity alerts and indicate that the prodrugs are safe within the tested concentrations. In conclusion, while in silico assessments raised concerns about potential hepatotoxicity, our in vitro studies promised the safety of the tested prodrugs, emphasizing the urgency of investigating their efficacy as prospective treatments for GNEM.As Doenças Raras (RDs) constituem um grande desafio. Quase 8000 RDs são conhecidas, mas apenas 200 têm tratamento. O desenvolvimento de fármacos é um processo longo e caro, tendo as ferramentas in silico ganho particular interesse na última década ao fornecer previsões sobre a metabolização e interação de fármacos com alvos biológicos. Defeitos na glicosilação estão na origem de uma família de doenças conhecidas como doenças congénitas da glicosilação (CDG). A Miopatia GNE (GNEM) é uma CDG ultra-rara causada por mutações no gene GNE responsável por codificar a enzima bifuncional UDP-N-acetilglucosamina 2-epimerase/ N-acetilmanosamina cínase que regula a biossíntese do ácido siálico. Até hoje, não há nenhuma terapia aprovada para a GNEM, mas a suplementação com ácido siálico e precursores tem sido estudada. Neste trabalho foram utilizadas ferramentas in silico para explorar as propriedades de absorção, distribuição, metabolismo, excreção e toxicidade, bem como as interações off-target dos novos pró-fármacos (PGNE 1-5) para o tratamento da GNEM. Está previsto estes pro-fármacos terem melhor absorção que a N-acetilmanosamina, atualmente em fase 2 de ensaios clínicos. No entanto, os pró-fármacos PGNE 1-5 apresentaram alguns alertas de toxicidade, nomeadamente relacionados com a hepatotoxicidade. Interações com as proteínas envolvidas na distribuição (glicoproteína P) e no metabolismo (citocromo P450 3A4 e carboxilesterase 1) foram propostas como sendo responsáveis por esses alertas. Para avaliar a extensão das previsões de hepatotoxicidade e a segurança dos pró-fármacos, estudos in vitro num modelo celular hepático e num modelo celular da GNEM foram realizados, respetivamente. Os ensaios de viabilidade celular não confirmam os alertas de toxicidade, porém os mesmos confirmaram a segurança dos pró-fármacos nas concentrações testadas. Em conclusão, apesar dos ensaios in silico terem levantado preocupações sobre o potencial hepatotóxico dos pró-fármacos, os ensaios in vitro realizados apontam para a segurança dos mesmos, enfatizando a importância de se estudar a eficácia dos pró-fármacos para o tratamento da GNEM.Videira, PaulaBarbosa, MarianaRUNCunha, Joana Sousa2023-11-222025-09-01T00:00:00Z2023-11-22T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10362/161275enginfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:44:09Zoai:run.unl.pt:10362/161275Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:58:28.180262Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
title |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
spellingShingle |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline Cunha, Joana Sousa Glycosylation GNE Myopathy Sialic acid Prodrugs Hepatotoxicity Domínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e Tecnologias |
title_short |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
title_full |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
title_fullStr |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
title_full_unstemmed |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
title_sort |
New therapeutic options for GNE Myopathy: in silico and in vitro approaches to accelerate drug discovery pipeline |
author |
Cunha, Joana Sousa |
author_facet |
Cunha, Joana Sousa |
author_role |
author |
dc.contributor.none.fl_str_mv |
Videira, Paula Barbosa, Mariana RUN |
dc.contributor.author.fl_str_mv |
Cunha, Joana Sousa |
dc.subject.por.fl_str_mv |
Glycosylation GNE Myopathy Sialic acid Prodrugs Hepatotoxicity Domínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e Tecnologias |
topic |
Glycosylation GNE Myopathy Sialic acid Prodrugs Hepatotoxicity Domínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e Tecnologias |
description |
Rare Diseases (RDs) pose a significant challenge. Almost 8,000 RDs are known, but only 200 have a treatment. The development of drugs is an extensive and costly process and in silico tools have gained a particular interest in the last decade by giving insights into drug metabolization and interaction with biological targets. Defective glycosylation leads to a family of RDs known as congenital disorders of glycosylation (CDG). GNE Myopathy (GNEM) is an ultra-rare CDG caused by mutations in the GNE gene responsible for encoding the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase that regulates the sialic acid biosynthesis. To date, there is no approved therapy for GNEM but supplementation approaches with sialic acid and its precursors have been studied. In this work, in silico tools were used to explore the absorption, distribution, metabolism, excretion and toxicity properties, as well as off-target interactions of five novel prodrugs (PGNE 1-5) for treating GNEM. These prodrugs are predicted to have a potential advantage in terms of absorption when compared with N-acetylmannosamine, which is currently in a phase 2 clinical trial. However, PGNE 1-5 display concerning toxicological indicators namely related to hepatotoxicity. These alerts may be attributed to interactions with proteins involved in distribution (P-glycoprotein) and metabolism (cytochrome P450 3A4 and carboxylesterase 1). To evaluate the extension of the hepatotoxicity predictions and the safety of the prodrugs, in vitro studies were conducted by using a hepatic and a GNEM cell model, respectively. The viability assays did not confirm the toxicity alerts and indicate that the prodrugs are safe within the tested concentrations. In conclusion, while in silico assessments raised concerns about potential hepatotoxicity, our in vitro studies promised the safety of the tested prodrugs, emphasizing the urgency of investigating their efficacy as prospective treatments for GNEM. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-11-22 2023-11-22T00:00:00Z 2025-09-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/161275 |
url |
http://hdl.handle.net/10362/161275 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138165746827264 |